Following yesterday’s deposit by Austria of its instrument of ratification of the Protocol on Provisional Application of the Agreement on the Unified Patent Court, the General Secretariat of the Council of the European Union has just declared that the Protocol has now entered into force. Similar statements were issued by the European Patent Office and the Preparatory Committee of the Unified Patent Court.

The Preparatory Committee also declared that this event signals the birth of the Unified Patent Court as an international organisation and that the last part of the preparatory work in establishing the Court, and in particular the recruitment of Judges, will now be finalized. It forecasts a timeline of no less than eight  months for the process to be completed and the UPC to start its operations. Germany will act as gatekeeper, depositing the instrument of ratification of the UPCA and hence allowing the Court to start operating as soon as the preparatory work is about to be completed (the UPCA will enter into force on the first day of the fourth month after the deposit of the German instrument of ratification).

The Preparatory Committee also announced that the inaugural meetings of the governing bodies of the Court, namely the Administrative Committee, the Advisory Committee and the Budget Committee, will soon take place. It is unclear whether these meetings will be preceded by the signing ceremony of the draft Declaration on the authentic interpretation of Article 3 of the Protocol, which had been anticipated by the Preparatory Committee to address the uncertainties following the United Kingdom’s withdrawal from the Unitary Patent System (for additional details, see here) and support the view that Article 3 of the Protocol is to be interpreted as mirroring Article 89 of the UPCA.

As additional confirmation of the commitment of the institutional stakeholders in having the system to start operating soon, the EPO yesterday also announced that it will introduce transitional measures with respect to European patent applications having reached the final phase of the grant procedure. These measures will be made available ahead of the entry into force of the Unitary Patent system. Further details will likely be released soon.

The Federal Government of Germany has just announced that it has deposited the instrument of ratification for the Protocol on the Provisional Application of the Agreement on a Unified Patent Court. This is a decisive step towards the start of UPC operations in the near future, after years of uncertainties.

As explained by the Preparatory Committee, for the Protocol to take effect its ratification by two more states is needed, which is expected to occur in the coming weeks (the point is confirmed in the press release issued by the Federal Government of Germany). This will pave the way for the final phase for the set-up of the Unified Patent Court: the UPC will be established in its full legal capacity and organizational capability and a number of further preparatory steps will be undertaken (including assembling the governing bodies of the Court, adopting all the secondary legislation prepared by the Preparatory Committee, finalizing the budget an IT systems, and resuming the recruitment and training of judges). As soon as the preparatory work will be sufficiently advanced to ensure that the UPC can start in an orderly manner, the last outstanding instrument of ratification of the UPCA itself will be deposited by Germany. The German Federal Government expects the UPC to become fully operational from mid-2022.

The remarks by the Federal Minister of Justice Christine Lambrecht leave no doubt on the dedication of the German government to proceed with the steps needed for the UPC to start operating as soon as possible. Also, they seem to confirm the inter-governmental intention to proceed swiftly, avoiding new agreements (and, possibly, ratifications) addressing the relocation of the competences of the London seat of the Central Division. Commenting the ratification of the Protocol, Federal Minister of Justice Christine Lambrecht stated: “With this step we have come a decisive step closer to the European patent reform, which is so important for innovative companies in Europe. The Unified Patent Court will come”.

With an order issued on 16 June 2021 (available here), the Court of Turin applied the proportionality principle in calibrating the scope of a preliminary injunction, with a carve out that excluded the application of the injunction to three ongoing supplies to health facilities.

The case concerned a number of patents owned by the plaintiff covering an aortic valve and its positioning system, two of which were held valid and infringed by the products of the defendant companies. In light of such findings, the Court issued an injunction, carving out from its scope three supplies to health facilities, two of which had already been performed and one of which had been awarded and was in the process of being performed. In order to do so, the Court applied Article 124(6) IP Code, which provides i.a. for the proportionality principle to be applied to remedies in patent cases and was invoked by the defendant companies.

Article 124(6) IP Code can be translated as follows:

“Removal or destruction, as well as prohibition of use, of items that constitute infringement of IP rights shall not be ordered when they belong to a person who makes only a personal or domestic use of them. In applying the corrective measures, the judicial authority must take account of the necessary proportion between the seriousness of the infringement and the corrective measures ordered, as well as of the interests of third parties”

This is the first time in Italy where a Court applies the proportionality principle to limit an injunction issued in the context of a patent infringement suit and does so by relying on Article 124(6) IP Code, whose application to injunctive relief had so far been questioned. The sole Italian precedent recalled by the Court of Turin (Court of Milan, 29 October 2019, Heraeus v. Biomet – available on darts-ip and commented here) concerned an injunction issued in a case of misappropriation of trade secrets, whereby the Court of Milan similarly applied the proportionality principle but relying on Article 124(6-bis) IP Code, which implements the Trade Secrets Directive (2016/943) and only applies to trade secrets, thereby granting a one-year “grace period” for its final injunction to take effect in relation to supplies to health facilities.

In any event, the arguments in favor of the application of the proportionality principle put forward by the Court of Turin closely mirror the ones previously brought by the Court of Milan. Indeed, as some readers may recall (see again our post commenting the decision here), the Milan judges limited in time the effects of the injunction issued in order to “safeguard the continuity of ongoing supplies to public administrations and hospital facilities”. A similar reasoning was adopted by the Court of Turin, taking account of the public interest to the proper functioning of the healthcare structures involved in the supply of the infringing products.

From a comparative perspective, the Court of Turin also explicitly referred to the principles expressed by the England and Wales High Court, which in a similar case had established the necessity to “ensure a balance between the [private] interest in maintaining the exclusivity conferred by the patent […] and the public interest in ensuring that patients with aortic stenosis receive appropriate treatment” (cf. Edwards Lifesciences v Boston Scientific [2018] EWHC 1256).

No mention was made instead to the later decision, by Justice Birss in Evalve v Edwards Lifesciences [2020] EWHC 514, whereby the English Court excluded application of the proportionality principle invoked by the alleged infringers to deny in the abstract the imposition of the injunction. It is worth noting, however, that in such case the Court granted the injunction in the face of an inter partes agreement which ensured a carve out for certain limited uses in which the patent holder’s aortic valve had proved unsuitable.

On 19 July, the Italian House of Representatives approved the amendment of the current Intellectual Property Code (“IPC”), as proposed by the conversion law of the so-called Recovery Law Decree (law decree 31 May 2021, no. 77). Upon proposal of the former Minister of Health, MP Giulia Grillo, the House of Representatives voted in favor of introducing Article 70-bis into the IPC. The new Article 70-bis, compulsory licensing in the event of a national health emergency, shall read as follows:

  1. If a national health emergency is declared compulsory licenses may be granted in order to overcome proven difficulties in supplying essential medicines or medical devices and in compliance with international and European obligations. These compulsory licenses shall grant licensees a non-exclusive and unalienable right to exploit production-relevant patents, mainly for supplying the Italian market, and shall be valid as long as the emergency period lasts or up to a maximum of twelve months from the end of the same;
  2. The compulsory license for the medicinal products referred to in paragraph 1 is granted by decree of the Minister of Health, in agreement with the Minister of Economic Development, subject to the opinion of the Italian Medicines Agency on the medicinal products’ essentiality and availability with respect to the current health emergency and after having heard the patentee. The same decree shall also provide the IPRs owner with appropriate compensation, which must take into account the economic value of the authorization;
  3. The compulsory license for the medical devices referred to in paragraph 1 is granted by decree of the Minister of Health, in agreement with the Minister of Economic Development, after having heard the opinion of the National Agency for Regional Health Services on the devices’ essentiality and availability with respect to the current health emergency, as well as the patentee. The same decree shall also provide the IPRs owner with appropriate compensation, which must take into account the economic value of the authorization.

The IPC is already familiar with the mechanism of compulsory licensing, which, according to Article 70, can be granted when the patentee has not exercised his patent rights within three years from grant or four years from filing (whichever is later), by manufacturing the patented product in the Italian territory, or importing patented products manufactured in a EU/EEA/WTO country, or when the patentee has implemented the invention in such a way as to result in serious disproportion to the country’s needs. The purpose of the new Article 70-bis is therefore to shorten the waiting time, ensuring that a patent covering essential medicines or medical devices can be licensed as soon as the emergency period arises and up to a maximum of twelve months after its end.

The amendment specifies both the competent authority and the procedure for issuing the compulsory license. In particular, the compulsory license shall be issued by decree of the Minister of Health, in agreement with the Minister of Economic Development, after having heard the patent owner, and after obtaining the opinion of the Italian Medicines Agency (“AIFA”), in case of medicinal products, or the National Agency for Regional Health Services, in case of medical devices. Moreover, Article 70-bis acknowledges appropriate compensation in favour of the patent owner; such compensation must take into account the economic value of the authorization.

Once the House of Representatives will have completed the legislative process, the amended bill will return to the Senate for final approval.

The amendment is available at the following link (see Article 56, still only available in Italian): http://documenti.camera.it/apps/emendamenti/getProposteEmendativeSeduta.aspx?contenitorePortante=leg.18.eme.ac.3146&tipoSeduta=1&sedeEsame=referente&urnTestoRiferimento=urn:leg:18:3146:null:null:com:0108:referente&dataSeduta=20210719&tipoListaEmendamenti=1

UPDATE:  

As a follow up to our previous blog post above, on 27 July also the Italian Senate has approved the amendment of the current Intellectual Property Code.

The conversion law entered into force on 31 July 2021 (Article 1 (8) of Law 29 July 2021, no. 108); accordingly, Article 70-bis, compulsory licensing in the event of a national health emergency, will be now introduced into the IPC.

Con una recente ordinanza del 16 giugno 2021 (disponibile online qui), il Tribunale di Torino ha ribadito la possibilità per il giudice di modulare il provvedimento inibitorio emesso in un caso di contraffazione brevettuale, facendo applicazione del principio di proporzionalità.

Nello specifico il giudice torinese, ritenuta la validità di due brevetti di proprietà delle società ricorrenti e la relativa contraffazione ad opera dei prodotti fabbricati e commercializzati dalle società resistenti (una valvola aortica ed il relativo sistema di posizionamento), ha inibito a queste ultime la fabbricazione, il commercio e l’utilizzo di tali prodotti contraffattivi, anche autorizzando il sequestro degli stessi.

Tuttavia, in considerazione dei diversi interessi in gioco e visto anche che le società resistenti avevano invocato la previsione dell’art. 124, comma 6, c.p.i., secondo cui “nell’applicazione delle sanzioni l’autorità giudiziaria tiene conto della necessaria proporzione tra la gravità delle violazioni e le sanzioni, nonché dell’interesse dei terzi”, il Tribunale di Torino ha ritenuto di modulare l’efficacia del provvedimento inibitorio – e, di riflesso, del sequestro – prevedendo che dagli stessi fossero esclusi i prodotti contraffattivi relativi a tre forniture, due già eseguite ed una già aggiudicata ed in fase di esecuzione, presso tre diverse strutture sanitarie.

Nel fare questo il giudice torinese ha richiamato con approvazione una precedente sentenza del Tribunale di Milano, emanata in una causa avente ad oggetto la violazione di segreti commerciali relativi a cementi ossei utilizzati in campo ortopedico, in cui già si era avuta analoga modulazione dal punto di vista temporale dell’inibitoria in applicazione del principio di proporzionalità (cfr. Tribunale di Milano, sentenza n. 9828, del 29 Ottobre 2019, la cui versione pubblica è disponibile su Darts-ip; la versione riservata, cui si ha accesso avendo lo studio assistito l’attrice in quel giudizio, non include informazioni di interesse per il profilo in esame).

Anche in quel caso, infatti, i giudici milanesi, accertata la sottrazione e l’illecito utilizzo dei segreti industriali di proprietà delle società attrici da parte delle società convenute per la produzione di cementi ossei replica di quelli prodotti dalle prime, avevano inibito a queste ultime la produzione, la commercializzazione, l’acquisto e la promozione di tali prodotti illeciti, limitando tuttavia l’efficacia temporale del comando inibitorio. Difatti, tenuto conto degli interessi in questione ed applicando il principio di proporzionalità, il Tribunale di Milano aveva stabilito che l’inibitoria non avrebbe avuto effetto per un periodo di tempo di un anno (c.d. “grace period”) con riferimento alle “forniture già in corso con pubbliche amministrazioni o comunque presidi ospedalieri”, così da salvaguardare l’attività di questi ultimi, consentendogli di ricorrere “a procedure ad evidenza pubblica urgenti per l’acquisto di prodotti equivalenti e per formare il proprio personale medico”.

I principi espressi dal Tribunale di Milano, che nell’emanazione dell’inibitoria ha preso in considerazione l’interesse pubblico relativo al corretto funzionamento delle strutture sanitarie coinvolte nella fornitura dei prodotti illeciti, sono stati ritenuti condivisibili dal Tribunale di Torino, che sul punto ha anche richiamato analoghi principi espressi dalla England and Wales High Court, che in un caso analogo aveva stabilito che è necessario “garantire un equilibrio tra l’interesse [privato] a mantenere l’esclusiva conferita dal brevetto […] e l’interesse pubblico di assicurare che i pazienti con stenosi aortica ricevano un trattamento appropriato” (cfr. Edwards Lifesciences v Boston Scientific [2018] EWHC 1256, espressamente citata dal Tribunale di Torino, che invece omette di citare la successiva decisione inglese in Evalve v Edwards Lifesciences [2020] EWHC 514, in cui l’applicazione del principio di proporzionalità, richiamata dagli asseriti contraffattori per negare in astratto l’irrogabilità dell’inibitoria, era stata esclusa, a fronte, tuttavia, di un accordo negoziale inter partes che assicurava un carve out per certi limitati usi in cui la valvola aortica del titolare del brevetto si fosse dimostrata non idonea).

Il Tribunale torinese, pertanto, ha scelto di modulare l’inibitoria pronunciata nel caso di specie al fine di salvaguardare l’interesse pubblico connesso all’attività delle strutture sanitarie che avevano già operato, o comunque già aggiudicato, la fornitura dei prodotti contraffattivi, tenuto anche conto della delicatezza della destinazione d’uso di questi ultimi.

L’ordinanza in commento, al pari della precedente sentenza del Tribunale di Milano, ha quindi sancito la possibilità per il giudice di modulare l’inibitoria emanata in caso di accertata violazione delle norme in materia di proprietà intellettuale, in applicazione del principio di proporzionalità e della necessità di contemperare l’interesse privato dei titolari di tali diritti di proprietà intellettuale con l’interesse pubblico legato alla corretta esplicazione dell’attività di cura dei pazienti delle strutture sanitarie.

Ed è verosimilmente questa la ragione per cui l’ordinanza – diversamente dai citati precedenti inglesi – non ha svolto un esame comparativo approfondito dell’impatto che l’inibitoria richiesta avrebbe avuto sulle strutture sanitarie, operando sulla base di quella che parrebbe una presunzione di prevalenza dell’interesse alla salute, superabile dal titolare del brevetto nei rari casi in cui avrà un interesse ad evitare una tale modulazione dell’ordine inibitorio per escludere forniture sanitarie già avviate.

It seems that the long-awaited clarification by the Court of Justice of the European Union (CJEU) on a number of open issues related to standard essential patent (SEPs) will have to wait a little longer after all.

Nokia and Daimler have indeed just announced in a joint press release that they have signed a patent licensing agreement, bringing an end to a dispute started in 2019 after initial licensing talks had failed. Under the agreement, whose terms remain confidential, Nokia licenses mobile telecommunications technology to Daimler and receives payment in return. The parties have also agreed to settle all pending litigation, including the complaint by Daimler against Nokia to the European Commission and the patent infringement case brought by Nokia before the Düsseldorf Regional Court which gave rise to the referral to the CJEU reported in our previous article (see also here for the official translation of the referral and the related order which has in the meantime been made available on the CJEU website).

The withdrawal of the case before the German national court entails that the Luxembourg judges will not be able to rule on the referred questions, which concerned not only the issue of component level licensing, but also a number of further major open issues dealt with by the previous case law (including i.a. confirmation that the implementer can make up without prejudice in the course of legal proceedings for duties of conduct that were not met in the pre-litigation phase, and a clarification as to whether the implementer’s unwillingness can be found without prior examination of whether the SEP holder’s own license offer was actually FRAND). The news of the settlement thus comes as a setback for the IP community which was looking forward to a new decision of the CJEU after Huawei v. ZTE, to clarify some of the still outstanding FRAND-related issues.

This new development and the open issues in the SEP world will be extensively discussed in the coming weeks and months. For example, the 3 days online conference entitled “6th IP and Competition Forum – A New World Order for FRAND” organized by OxFirst will have sessions focusing on the matters which were at the hearth of the CJEU referral such as component-level licensing and the details of the FRAND defences, as well as global FRAND rates-setting, anti-suit injunctions and proportionality of injunctions. Free tickets are still available through application with Oxfirst.

In the recent decision of April 29, 2021, the EUIPO Cancellation Division provided relevant clarification concerning the most appropriate evidence to prove the use of a trademark in relation to specific goods and services claimed in large categories.

Facts of the proceedings

In February 2019, an application for revocation for non-use of the EU word trademark “NUTELLA” owned by Ferrero S.p.A. was filed. The application concerned a large number of goods and services claimed in Classes 29, 30, 32, and 43, partly related to the core business of the well-known snack and confectionery producer Ferrero.

In order to prove the trademark use, the owner filed a large documentation including invoices, brochures, advertising materials, press releases, and market surveys on the reputation of the “NUTELLA” trademark in Europe.

Case law principles referred to by the EUIPO

In its examination of the documentation filed by the trademark owner, the EUIPO referred to certain principles regarding the proof of use of the trademark for specific goods (14/07/2005, T-126/03, Aladin, EU:T:2005:288).

In particular, the EUIPO clarified that in case of trademarks registered for a broad category of goods or services – within which different sub-categories may be identified – proof of use for a part of those goods or services affords protection only for the sub-category to which the goods or services for which the trademark was actually used belong. On the contrary, if a trademark has been registered for goods or services so precisely defined and circumscribed that no sub-categories within the relevant class are identifiable, proof of use of the trademark for those goods or services covers the entire class.

The decision of the EUIPO

In the light of the above observations, the EUIPO found evidence of use only for certain goods in Class 30 related to the leading products and core business of the owner, namely: biscuits, chocolate paste, cocoa and hazelnuts based creams in the form of spreads, chocolate pastes, chocolate products, chocolate pastries.

On the contrary, the EUIPO considered insufficient the evidence filed by the owner for the additional goods and services claimed in Classes 29, 30, 32, and 43, in respect of which it granted the revocation. In particular, the EUIPO widely examined the evidence provided in relation to tea, confectionery, bread and ices in Class 30:

  • with reference to tea, the EUIPO examined the documentation filed attesting to the use of the “NUTELLA” trademark  in combination with the “ESTATHÈ” trademark  in a co-branding initiative with the well-known producer of tea-based drinks. According to the EUIPO, the consumer is well aware of the fact that these are two trademarks that distinguish different products that are sold within the same package only for a matter of convenience. Therefore, the “NUTELLA” trademark identifies only the snack of hazelnut chocolate spread and breadsticks, while the “ESTATHÈ” trademark identifies the tea-based drink.
  • with reference to confectionery, the EUIPO clarified that this category of products – which includes sugared almonds, sweets and chocolates – does not present an appreciable degree of similarity with the products for which the owner has proved the use of the contested trademark, i.e. biscuits and creams in the form of spreads.
  • with reference to bread, the EUIPO stated that the snack marketed by the owner consisting of spreadable cream and breadsticks does not constitute suitable evidence of the use of the trademark. In fact, the goods sold by the owner are snacks in which the prevailing element is chocolate and hazelnuts based creams in the form of spreads, while the breadsticks are accessory components of a snack that, as a whole, meets a consumer need clearly different from the one that could be satisfied with the purchase of bread.
  • With reference to edible ices, the EUIPO held that the evidence of the trademark use for semi-finished preparations for the preparation of ices refers to different goods which do not include the category of edible ices.

Moreover, with reference to the services for providing food and drink in Class 43, the EUIPO considered the evidence filed by the owner to be insufficient. In fact, the documentation presented, while showing the setting up of a “NUTELLA Concept Bar” within the EXPO MILAN 2015 exhibition event, as well as a “NUTELLA” gourmet corner within the Hilton hotel in Venice, was not suitable to prove the volume of sales or turnover generated by these activities.

Finally, the EUIPO noted the lack of documents that could refer to the trademark use for the remaining disputed goods and services, including fruit, jellies, jams, coffee, spices and beverages.

 

ITALIAN VERSION

Prova d’uso del marchio per ampie categorie di prodotti e servizi: la recente decisione dell’EUIPO per il marchio “NUTELLA”

Con una recente decisione del 29 aprile 2021, la Divisione di Annullamento dell’EUIPO ha fornito rilevanti indicazioni in merito alle prove più idonee a dimostrare l’uso effettivo di un marchio in relazione a specifici prodotti e servizi rivendicati in ampie categorie merceologiche.

Fatti del procedimento

Nel febbraio del 2019, è stata presentata una domanda di decadenza per non uso del marchio denominativo dell’Unione europea “NUTELLA” di titolarità Ferrero S.p.A. La domanda ha avuto ad oggetto un gran numero di prodotti e servizi rivendicati nelle classi 29, 30, 32 e 43, in parte relativi al core business della nota azienda di snack e dolciumi.

Per dimostrare l’uso effettivo del marchio, la titolare ha presentato copiosa documentazione tra cui fatture, dépliant, materiali pubblicitari, articoli di stampa e studi di mercato sulla notorietà del marchio “NUTELLA” in ambito europeo.

Principi giurisprudenziali richiamati dall’EUIPO

Nell’esaminare la documentazione presentata dal titolare del marchio, l’EUIPO ha richiamato alcuni principi relativi alla prova dell’uso del marchio per i singoli prodotti rivendicati  (14/07/2005, T-126/03, Aladin, EU:T:2005:288).

In particolare, l’EUIPO ha chiarito che nel caso di marchi registrati per una ampia categoria di prodotti o servizi – al cui interno  possono essere distinte differenti sottocategorie inquadrabili autonomamente – la prova d’uso del marchio per una parte di detti prodotti o servizi comporta la tutela unicamente per la sottocategoria cui appartengono i prodotti o servizi per i quali il marchio è stato effettivamente utilizzato. Viceversa, qualora un marchio sia stato registrato per prodotti o servizi definiti in modo talmente preciso e circoscritto da non poter operare sottocategorie all’interno della relativa classe, la prova d’uso del marchio per tali prodotti o servizi ricomprende l’intera categoria.

Decisione dell’EUIPO

Alla luce di tali considerazioni, l’EUIPO ha ritenuto provato l’uso solo per alcuni prodotti della classe 30 riconducibili ai prodotti di punta e al core business della titolare, ossia: biscotti, pasta di cioccolato, creme spalmabili a base di cacao e nocciole, pasticceria a base di cioccolato, prodotti di cioccolato, pasticceria a base di cioccolato.

Al contrario, l’EUIPO ha ritenuto insufficienti le prove depositate dalla titolare per gli ulteriori prodotti e servizi rivendicati nelle classi 29, 30, 32 e 43, nei confronti dei quali ha accolto la domanda di decadenza. In particolare, l’Ufficio ha ampiamente esaminato le prove fornite in relazione ai prodotti tè, confetteria, pane e gelati della classe 30:

  • con riferimento al tè, l’Ufficio ha esaminato la documentazione depositata attestante l’uso del marchio “NUTELLA” in combinazione con il marchio “ESTATHÈ” nell’ambito di una iniziativa di co-branding con la nota azienda produttrice di bevande a base di tè. Secondo l’EUIPO, il consumatore è ben cosciente del fatto che si tratta di due marchi che contraddistinguono prodotti differenti che vengono venduti all’interno della stessa confezione solo per una questione di comodità. Pertanto, il marchio “NUTELLA” identifica unicamente lo snack di crema spalmabile al cioccolato alla nocciola e grissini, mentre il marchio “ESTATHÈ” identifica la bevanda a base di tè.
  • con riferimento alla confetteria, l’EUIPO ha chiarito che tale categoria di prodotti – che ricomprende confetti, caramelle e cioccolatini – non presenta un grado di affinità apprezzabile rispetto ai prodotti per cui la titolare ha provato l’uso effettivo del marchio contestato, ossia biscotti e creme spalmabili.
  • con riferimento al pane, l’EUIPO ha stabilito che lo snack venduto dalla titolare costituito da crema spalmabile e grissini non costituisce una prova idonea dell’uso effettivo del segno. Infatti, i prodotti venduti dalla titolare sono snack nei quali l’elemento prevalente è la crema spalmabile al cioccolato alla nocciola, mentre i grissini sono componenti accessorie di uno snack che, nel suo complesso, risponde a un bisogno del consumatore chiaramente diverso rispetto a quello che potrebbe essere soddisfatto con l’acquisto di pane.
  • con riferimento ai gelati commestibili, l’EUIPO ha ritenuto che la prova dell’uso del marchio per preparati semilavorati per la preparazione di gelati si riferisce a prodotti diversi che non includono la categoria di gelati commestibili.

Inoltre, con riferimento ai servizi di fornitura di alimenti e bevande in classe 43, l’Ufficio ha ritenuto insufficienti le prove depositate dalla titolare. Ed infatti, la documentazione depositata, pur dimostrando l’avvenuto allestimento di un “NUTELLA Concept Bar” in seno all’evento fieristico EXPO MILANO 2015, nonché un “NUTELLA” corner gourmet all’interno dell’hotel Hilton a Venezia, non è risultata idonea a provare il volume delle vendite o del fatturato generato da queste attività.

Infine, l’EUIPO ha rilevato la mancanza di documenti che possano riferirsi all’uso del marchio per i rimanenti prodotti e servizi contestati, tra cui frutta, gelatine, marmellate, caffè, spezie e bevande.

The European Patent Office (EPO) released the Patent Index 2020, which gives an overview of the filing activities in the EU during the past year. Despite the Covid-19 pandemic’s dramatic impact on all aspects of the economy, the number of patent applications filed only slightly declined with a 0.7% decrease compared to 2019.

In this scenario, Italy emerges as one of the fastest-growing European countries in the healthcare innovation sector, achieving an increase in applications well above the average in pharmaceutical patents. Also worth noting is a considerable growth in medical technology, which is now the fourth most relevant technical field in the country.

Medical technologies, pharmaceuticals, and biotechnology all registered strong performance overall at the EPO level as well. Healthcare innovation was the main driver of European patent applications in 2020, with medical technologies in the lead spot among all tech sectors and major growth in the pharmaceuticals and biotechnology fields.

These three fields lead the trend with growths of +2.6%, +10.2% and +6.3% respectively. Just these three technical fields alone comprise some 16.7% of all patent applications filed with the EPO in 2020.

Interestingly, the EPO Patent Index 2020 itself attributes most of the increase of patent filings in the medical technology, pharmaceuticals and biotechnology fields to the impact of the Covid-19 pandemic in encouraging innovation. In this framework, European countries maintained a share of almost half of all patent applications filed, while China (+9.9%) and South Korea (+9.2%) saw the most significant growth.

Looking more in detail at the performance of EU countries, applications from Germany, Europe’s largest country of origin, decreased by 3.0% in 2020, similarly to those from The Netherlands (-8.2%) and UK (-6.8%). Italy, on the other hand, saw a remarkable growth of 2.9% and is currently ranked 10th for the overall number of patent applications filed.

Italy registered in particular a considerable growth in the medical technology, pharmaceuticals, and chemical engineering sectors, in line with the general trend outlined above. In particular, Italy plays a key role in pharmaceutical innovation with a significant growth of over 22% compared to 2019, preceded only by the furniture and games sector. Moreover, Italy registered a 6.0% increase of applications in the medical technology sector, which is above the average increase in the top-10 countries for the sector.

Italy thus continued the positive trend in terms of innovation growth already ongoing over the past years, in particular in the healthcare sector that is one of the highlights of its industrial landscape.

Con recente sentenza n. 179 del 29 gennaio 2021, il Tribunale di Genova ha liquidato il danno da contraffazione di una privativa varietale raddoppiando l’importo calcolato con il criterio della royalty ex art. 125 CPI.

Il caso aveva ad oggetto la illecita moltiplicazione e commercializzazione, da parte di un distributore di sementi emiliano, della nota varietà di grano tenero denominata ‘Bandera’, protetta a livello europeo dal gruppo sementiero francese RAGT e gestita dalla società francese SICASOV in qualità di mandatario.

Il Tribunale di Genova, dopo aver accertato la condotta contraffattiva, ha quantificato ex art. 125 CPI il danno da lucro cessante subito dalle attrici, applicando il criterio della royalty.

L’importo così ottenuto è stato poi raddoppiato dai giudici genovesi, accogliendo la specifica richiesta formulata dalle attrici. E ciò al fine sia di indennizzare tutte le perdite effettivamente subite dal titolare della privativa e dal suo mandatario, sia di evitare che il risarcimento risultasse in qualche misura premiale per l’autore della violazione.

Infatti, applicando il criterio della royalty ‘senza correttivi’ si corre il rischio di incentivare il contraffattore, che si ritroverebbe a pagare, molto tempo dopo l’avvio della condotta illecita e solo a seguito di un procedimento giudiziario, lo stesso importo normalmente richiesto al licenziatario.

Il principio della maggiorazione della royalty è già applicato con una certa frequenza dalla giurisprudenza italiana nei casi di contraffazione di diritti IP. Generalmente, il tasso di royalty individuato caso per caso viene aumentato di due o tre punti percentuali ovvero raddoppiato, proprio per non riconoscere al contraffattore un trattamento premiale.

La sentenza in commento si segnala per essere una delle prime pronunce ad aver esteso il suddetto principio anche in materia di contraffazione di privative varietali, avvicinandosi così al criterio delineato dall’art. 18, Reg. CE n. 1768/95. Tale disposizione – applicabile esclusivamente ai comportamenti tenuti dalle aziende agricole in violazione dei limiti imposti dal c.d. ‘privilegio dell’agricoltore’ – prevede che il risarcimento del danno dovuto al titolare “comprende per lo meno un importo forfettario pari a quattro volte l’ammontare da corrispondere per la produzione soggetta a licenza di una quantità equivalente di materiale di moltiplicazione di varietà protette delle rispettive specie vegetali nella stessa zona”.

I giudici genovesi, pur ritenendo non applicabile al caso di specie la norma europea (per il fatto che formalmente il convenuto non svolge attività agricola), hanno dimostrato particolare sensibilità per un’equa quantificazione del danno da contraffazione subito dai costitutori di nuove varietà vegetali. In tali casi, infatti, il costitutore ha difficoltà ad accertare l’entità della violazione: le vendite delle varietà protette – moltiplicate illegalmente – vengono spesso contabilizzate senza indicare la specifica denominazione della varietà, bensì con riferimenti generici (es. seme grano tenero/grano tenero da risemina), che non permettono una esatta determinazione del numero di semi o piante/frutti venduti. Tra l’altro, la contabilità delle aziende agricole si rivela, alle volte, lacunosa. Ciò rende impossibile un congruo ristoro del danno subito dal costitutore.

Si auspica, perciò, un utilizzo sempre maggiore da parte delle Corti italiane del principio del raddoppio della royalty nei casi di contraffazione di privative varietali, sperando di poter giungere anche alla piena applicazione dell’art. 18, Reg. CE n. 1768/95 (nei casi previsti dalla stessa norma).

Solo in questo modo si riuscirebbe – senza fare ricorso alla categoria dei danni punitivi, non contemplati dall’ordinamento italiano – a risarcire in modo soddisfacente i danni subiti dal costitutore/titolare di privative varietali e scoraggiare la contraffazione sempre più dilagante nel settore varietale.

The long awaited ‘SEPs Expert Group report’ has been published on Wednesday 10 February on the European Commission’s website (available here). As readers will recall (see here for further details and group members), the expert group was set up by the Commission in July 2018, with the task of providing economic, legal and technical expertise to assist the Commission in considering policy measures to ensure a balanced framework for the efficient licensing and valuation of standard essential patents (SEPs).

The expert group produced a massive report (230 pages), focusing on a broad range of highly debated topics, such as the need to increase transparency about SEPs and SEPs licensing, where to license in the value chain, how to establish fair and reasonable terms, when licensing conditions are non-discriminatory, how to facilitate negotiations and under what conditions injunctive relief should be available.

Interestingly, and reflecting the controversial nature of most topics, the report does not provide individual solutions (most importantly to the crucial issue of component level licensing in the value chain), and is instead more concerned about setting the framework and providing a pluralist account of the various positions (but this did not prevent one of the experts from writing a dissenting opinion – starting at page 187 of the report).

A few unanimous guidelines are nonetheless provided, as exemplified in the extracts below, confirming i.a. the centrality of the non-discrimination requirement (in contrast with a number of recent court decisions in Europe, including the UK Supreme Court decision in Unwired Planet – see here for additional details):

  • The non-discrimination (ND) commitment requires the licensor to treat similarly situated parties in a similar manner. In the EU Treaty, a similar requirement follows from Article 102(c) TFEU, which prohibits dominant firms to engage in anti-competitive discrimination. It is generally agreed that the ND commitment does not require the SEP holder to offer the exact terms and conditions to all licensees. A SEP holder should be allowed to respond to different market situations by offering different licensing terms. However, in the presence of similarly situated implementers, differences need to be objectively justified based on a holistic view of the relevant elements, such as sales volumes, certainty of royalty payments, geographic scope, etc.
  • Volume discounts, lump sum discounts and annual royalty caps are generally acceptable if offered to competitors that are similarly situated unless they greatly favor one or more licensees without any added benefits to the licensor.
  • An offer falls outside the Fair and Reasonable (FR) range if the SEP holder’s compensation exceeds the incremental value that the patented technology adds to the licensed product. The terms and conditions on offer should not reflect any hold-up value, which may result from irreversible choices made by licensees during the development or the implementation of a standard. A licensing offer also falls outside the FR range if it fails to remunerate the SEP holder for the value added created in the product implementing the standard. In other words, a FR license should not reward hold-out, i.e. the unlicensed use of the patented technology by refusing to enter into good faith license negotiations or by delaying such negotiations.

As said, the report does not provide unanimous guidelines on component level licensing (i.e. where in the value chain licensing should take place). A number of principles that could guide the licensing of SEPs in the value chain have nonetheless been set out by some of the experts and have found room in the executive summary. These principles are the following:

  • It may be more efficient if all relevant SEPs are licensed at a single level in the value chain (such level being dependent on the specific features of the vertical at stake).
  • The royalty for a license for a SEP portfolio that is fully implemented in an end-product should be the same, no matter where in the value chain licensing takes place.
  • The FRAND royalty is a cost element in the price of a component and should be passed on downstream.

A more detailed post may follow after we will all have had the time to digest all proposals. In the meantime, a number of interesting insights in the way the report was drafted and some of the considerations behind the positions taken on the main themes have already been provided by one of the group members (see here), underlining one of the main omissions in the report, namely the role and scope judicial FRAND determinations should have and the interaction between parallel court proceedings where one court has already been seized with a request for global determination.